Provided by Tiger Trade Technology Pte. Ltd.

Carpenter Technology

387.10
-4.0700-1.04%
Post-market: 387.100.00000.00%19:30 EDT
Volume:688.10K
Turnover:265.36M
Market Cap:19.18B
PE:36.80
High:391.02
Open:384.84
Low:379.94
Close:391.17
52wk High:625.99
52wk Low:233.78
Shares:49.56M
Float Shares:48.15M
Volume Ratio:0.95
T/O Rate:1.43%
Dividend:0.80
Dividend Rate:0.21%
EPS(TTM):10.52
EPS(LYR):10.52
ROE:25.75%
ROA:11.87%
PB:8.61
PE(LYR):36.80

Loading ...

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

GlobeNewswire
·
Jun 08

Lyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansion

GlobeNewswire
·
Jun 08

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

GlobeNewswire
·
Jun 06

Fate Therapeutics Showcases Data from FT819 and FT839 Programs at the European Congress of Rheumatology Annual Meeting

GlobeNewswire
·
Jun 04

Carpenter Technology Director Steven E. Karol disposes of 2,000 common shares worth $975,478.80

Reuters
·
Jun 04

Carpenter Technology director John Anastasio Hart disposes of 250 common shares worth $115,470.33

Reuters
·
Jun 02

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

GlobeNewswire
·
Jun 01

Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting

GlobeNewswire
·
Jun 01

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

GlobeNewswire
·
May 31

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

GlobeNewswire
·
May 30

PeproMene Bio Announces Oral Presentation at EHA 2026 Highlighting Favorable Safety and Durable Responses with PMB-CT01 (BAFF-R CAR T-Cell Therapy) in B-cell Lymphomas, Including After Prior CD19 CAR T-Cell Failure

prnewswire
·
May 28

Navigating the Pitfalls of Offshore Trusts as CRS 2.0 Implementation Approaches

Deep News
·
May 27

Carpenter Technology: This Stock Will Melt Up -- Barron's

Dow Jones
·
May 23

Analysts’ Top Industrial Goods Picks: Carpenter Technology (CRS), Brambles (BMBLF)

TIPRANKS
·
May 22

Carpenter Technology: This Stock Will Melt Up -- Barrons.com

Dow Jones
·
May 21

Antengene Appoints Dr. Bing Hou as Chief Scientific Officer to Lead Innovation-Driven R&D Strategy and Advance Next-Generation Pipeline

prnewswire
·
May 20

J.P. Morgan Remains a Buy on Carpenter Technology (CRS)

TIPRANKS
·
May 19

Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 15

Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

GlobeNewswire
·
May 14

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting

GlobeNewswire
·
May 14